Press Release: Exact Sciences Schedules First Quarter 2025 Earnings Call

Dow Jones
01 Apr

Exact Sciences Schedules First Quarter 2025 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--April 01, 2025-- 

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

First quarter 2025 webcast & conference call details

 
Date:         Thursday, May 1, 2025 
Time:         5 p.m. ET 
Webcast:      The live webcast can be accessed at www.exactsciences.com 
Telephone:    Domestic callers, dial 888-330-2384 International callers, dial 
              +1 240-789-2701 Access code for both domestic and international 
              callers: 4437608 
 

A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard$(R)$ and Oncotype(R) tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250401524918/en/

 
    CONTACT:    Derek Leckow 

Exact Sciences Corp.

investorrelations@exactsciences.com

608-893-0009

 
 

(END) Dow Jones Newswires

April 01, 2025 06:00 ET (10:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10